Menu Search
Equities

Biodexa Pharmaceuticals PLC

5MP:FRA

Biodexa Pharmaceuticals PLC

Actions
  • Price (EUR)0.885
  • Today's Change-0.025 / -2.75%
  • Shares traded2.50k
  • 1 Year change-95.35%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 18:23 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

  • Revenue in USD (TTM)477.05k
  • Net income in USD-8.86m
  • Incorporated2014
  • Employees21.00
  • Location
    Biodexa Pharmaceuticals PLC1 Caspian Point, Caspian WayABINGDON CF10 4DQUnited KingdomGBR
  • Phone+44 123 584 1575
  • Websitehttps://www.biodexapharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		5MP:FRA since
announced		Transaction
value
Varian Biopharmaceuticals IncAnnounced18 May 202318 May 2023Announced2,112.50%3.68m
Data delayed at least 15 minutes, as of May 10 2024 18:23 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.